Another possible mechanism of action is the preferential exertion of antibody- dependent cellular cytotoxicity on HER2-overexpressing cancer cells. [62] Trastuzumab contains an immunoglobulin G1 ...

We also need to understand mechanisms for resistance to trastuzumab deruxtecan as a single agent so we can develop combination therapies to further improve outcomes in this setting.” Trastuzumab ...

pointed to the potential for trastuzumab deruxtecan to address unmet need. “This is really, really compelling data,” he said. The ADC mechanism of delivering therapy “right to the source ...

Trastuzumab deruxtecan-THP was associated with a statistically significant and clinically meaningful improvement in pathologic complete response rate vs standard of care. The DESTINY-Breast11 ...

October 01, 2024--(BUSINESS WIRE)--AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for ENHERTU ® (fam-trastuzumab deruxtecan ... the FDA action date for ...

A regulatory decision is expected during the first quarter of 2025. The Food and Drug Administration has accepted for Priority Review the supplemental Biologics License Application (sBLA) for ...

--(BUSINESS WIRE)-- Positive results from the DESTINY-Breast09 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated a highly statistically significant ...

and we look forward to continuing to work with our partners within the drug reimbursement ecosystem to unlock additional mechanisms for accelerating access to more medicines in the future." ...

With a median progression-free survival of more than three years, the DESTINY-Breast09 results show trastuzumab deruxtecan combined with pertuzumab has the potential to become a new first-line ...

With a median progression-free survival of more than three years, the DESTINY-Breast09 results show trastuzumab deruxtecan combined with pertuzumab has the potential to become a new first-line ...